tiprankstipranks
Trending News
More News >
Oxford BioDynamics (GB:OBD)
:OBD

Oxford BioDynamics (OBD) AI Stock Analysis

Compare
25 Followers

Top Page

GB

Oxford BioDynamics

(LSE:OBD)

Rating:50Neutral
Price Target:
0.50p
▲(25.00%Upside)
The overall score is influenced primarily by financial challenges and unattractive valuation metrics, despite positive corporate events. Technical indicators show mixed signals, adding uncertainty to the stock's short-term outlook.

Oxford BioDynamics (OBD) vs. iShares MSCI United Kingdom ETF (EWC)

Oxford BioDynamics Business Overview & Revenue Model

Company DescriptionOxford BioDynamics (OBD) is a biotechnology company specializing in the development of precision medicine tests based on epigenetic biomarkers. The company operates within the healthcare and life sciences sectors, focusing on the use of its proprietary EpiSwitch technology platform to create diagnostic and prognostic solutions. These solutions aim to improve patient outcomes by offering personalized healthcare insights in areas such as oncology, immunotherapy, and chronic diseases.
How the Company Makes MoneyOxford BioDynamics generates revenue through the commercialization of its EpiSwitch technology. The company licenses its biomarker discovery and testing capabilities to pharmaceutical companies and healthcare providers, enabling them to develop personalized medicine solutions and improve clinical trial outcomes. Additionally, OBD offers its own suite of diagnostic tests directly to healthcare providers and patients, further expanding its revenue streams. Key partnerships with major pharmaceutical companies enhance its market reach and provide substantial collaboration opportunities, contributing significantly to its earnings. The company's revenue model also includes service agreements for biomarker discovery and validation projects, as well as potential royalties from products developed using OBD's technology.

Oxford BioDynamics Financial Statement Overview

Summary
Oxford BioDynamics faces substantial financial challenges with consistent net losses, rising leverage, and negative cash flows. Although there are some assets and equity, these are diminishing, indicating potential liquidity and solvency concerns.
Income Statement
30
Negative
Oxford BioDynamics shows a challenging financial trajectory with consistent net losses over the past years. The gross profit margin is low, and net income has been negative, indicating unprofitability. Revenue growth has been erratic, with no clear upward trend. EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high costs relative to revenue.
Balance Sheet
35
Negative
The balance sheet presents concerns, particularly in rising debt levels relative to equity, which has led to a rising debt-to-equity ratio. Return on equity is negative due to consistent net losses, and the equity ratio has decreased, indicating increased leverage and financial risk. However, there is still some equity cushion available, albeit shrinking.
Cash Flow
40
Negative
Cash flow analysis indicates significant strains with negative free cash flow and operating cash flow over the years. There was a notable decline in free cash flow growth rate, highlighting cash generation issues. Operating cash flow to net income ratio is negative, reinforcing operational cash challenges. Financing activities have been critical in supporting cash needs.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
617.00K636.00K510.00K154.00K341.00K456.00K
Gross Profit
-7.49M289.00K266.00K116.00K-557.00K-166.00K
EBIT
-12.43M-12.89M-11.03M-8.60M-7.51M-4.95M
EBITDA
-9.32M-10.27M-9.84M-6.16M-6.43M-4.42M
Net Income Common Stockholders
-11.11M-11.57M-10.83M-6.71M-6.68M-4.31M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.19M2.83M5.25M999.00K4.34M11.51M
Total Assets
11.07M12.11M16.13M11.34M15.38M15.35M
Total Debt
6.00M5.74M6.44M6.14M6.59M541.00K
Net Debt
4.82M3.91M1.19M5.16M4.41M-5.58M
Total Liabilities
9.44M7.75M10.07M8.76M8.69M1.77M
Stockholders Equity
1.62M4.36M6.05M2.59M6.68M13.56M
Cash FlowFree Cash Flow
-7.46M-10.77M-9.01M-6.08M-9.01M-3.86M
Operating Cash Flow
-6.71M-10.17M-8.29M-5.18M-5.92M-3.40M
Investing Cash Flow
1.68M-1.49M-691.00K1.25M2.83M4.58M
Financing Cash Flow
5.03M8.25M13.42M2.56M-804.00K-181.00K

Oxford BioDynamics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.40
Price Trends
50DMA
0.41
Negative
100DMA
0.47
Negative
200DMA
1.43
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
51.96
Neutral
STOCH
41.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.41, and below the 200-day MA of 1.43, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 41.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
GBIXI
62
Neutral
£10.43M-13.85%7.27%39.64%
59
Neutral
£16.42M-137.62%10.50%-9.60%
54
Neutral
£6.87M-99.43%17.39%96.02%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
GBOBD
50
Neutral
£7.83M-222.16%24.71%38.28%
GBFAB
44
Neutral
£7.56M-129.49%14.12%78.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:OBD
Oxford BioDynamics
0.40
-7.42
-94.88%
GB:IXI
IXICO plc
11.50
4.62
67.15%
GB:FAB
Fusion Antibodies Plc
6.65
3.30
98.51%
GB:AREC
Arecor Therapeutics PLC
43.50
-84.00
-65.88%
GB:APTA
Aptamer Group Plc
0.33
-0.39
-54.17%

Oxford BioDynamics Corporate Events

Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
Oxford BioDynamics’ Oxford Lab Achieves UKAS Accreditation for EpiSwitch® Tests
Positive
May 9, 2025

Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.

Other
Oxford BioDynamics Director Increases Stake, Signaling Confidence
Positive
Apr 10, 2025

Oxford BioDynamics announced that Non-Executive Director Peter Presland has purchased 3,398,553 ordinary shares, representing approximately 0.17% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s future prospects and could positively influence stakeholder perceptions and market positioning.

Other
Oxford BioDynamics CFO Executes Share Transfer
Neutral
Apr 2, 2025

Oxford BioDynamics Plc announced a transaction involving its CFO, Paul Stockdale, who transferred 791,176 ordinary shares into his ISA through a sale and repurchase process. This transaction, conducted on the London Stock Exchange, leaves Stockdale with a beneficial interest in 3,077,919 shares, representing 0.16% of the company’s issued share capital. This move is part of routine financial management and does not indicate any significant change in company operations or strategy.

Shareholder Meetings
Oxford BioDynamics Successfully Passes AGM Resolutions
Positive
Mar 28, 2025

Oxford BioDynamics Plc announced the successful passing of all resolutions at its Annual General Meeting. This development underscores the company’s continued commitment to advancing precision medicine through its innovative diagnostic tests, potentially enhancing its market position and stakeholder confidence.

Executive/Board Changes
Oxford BioDynamics Strengthens Board with New Appointment
Positive
Mar 17, 2025

Oxford BioDynamics has announced the appointment of Peter Presland as a Non-Executive Director and Chair of the Audit Committee, succeeding Matthew Wakefield. Presland brings extensive experience in business management and corporate governance, which is expected to enhance the board’s independence and governance capabilities. This strategic board change is anticipated to positively impact the company’s operational and governance structure, potentially benefiting stakeholders by strengthening the company’s leadership and oversight.

Business Operations and StrategyRegulatory Filings and Compliance
Oxford BioDynamics Announces Change in Major Holdings
Neutral
Mar 14, 2025

Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. The transaction has led to a decrease in the total percentage of voting rights held by Spreadex LTD, which could impact the company’s influence on corporate decisions and its strategic positioning within the industry.

Product-Related AnnouncementsBusiness Operations and Strategy
Oxford BioDynamics Expands Partnership with Bupa UK for Prostate Cancer Test Coverage
Positive
Mar 13, 2025

Oxford BioDynamics has expanded its partnership with Bupa UK insurance to include coverage for its EpiSwitch® PSE prostate cancer test. This strategic agreement enhances access to the PSE test for Bupa’s 3.9 million customers, particularly those with raised PSA levels but no high-risk factors or symptoms. The PSE test, known for its high accuracy and positive predictive value, aims to improve early prostate cancer diagnosis and reduce unnecessary procedures, aligning with Bupa’s commitment to advanced cancer care.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.